CN110506708B - 一种阿尔茨海默症小鼠模型及评价方法 - Google Patents
一种阿尔茨海默症小鼠模型及评价方法 Download PDFInfo
- Publication number
- CN110506708B CN110506708B CN201910904177.7A CN201910904177A CN110506708B CN 110506708 B CN110506708 B CN 110506708B CN 201910904177 A CN201910904177 A CN 201910904177A CN 110506708 B CN110506708 B CN 110506708B
- Authority
- CN
- China
- Prior art keywords
- mouse
- mice
- tau
- group
- alzheimer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 208000024827 Alzheimer disease Diseases 0.000 title claims abstract description 27
- 238000010172 mouse model Methods 0.000 title claims abstract description 19
- 238000011156 evaluation Methods 0.000 title claims description 7
- 241000699670 Mus sp. Species 0.000 claims abstract description 69
- 238000012360 testing method Methods 0.000 claims abstract description 30
- 210000003710 cerebral cortex Anatomy 0.000 claims abstract description 9
- 210000001320 hippocampus Anatomy 0.000 claims abstract description 9
- 230000003542 behavioural effect Effects 0.000 claims abstract description 8
- 230000002490 cerebral effect Effects 0.000 claims abstract description 5
- 241000699666 Mus <mouse, genus> Species 0.000 claims description 57
- 238000002474 experimental method Methods 0.000 claims description 43
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 claims description 19
- 239000008280 blood Substances 0.000 claims description 17
- 210000004369 blood Anatomy 0.000 claims description 17
- 210000005013 brain tissue Anatomy 0.000 claims description 17
- 238000010186 staining Methods 0.000 claims description 17
- 210000002569 neuron Anatomy 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 12
- 210000002682 neurofibrillary tangle Anatomy 0.000 claims description 11
- 239000002953 phosphate buffered saline Substances 0.000 claims description 10
- 238000001514 detection method Methods 0.000 claims description 8
- 210000003463 organelle Anatomy 0.000 claims description 8
- 230000005540 biological transmission Effects 0.000 claims description 7
- 210000001519 tissue Anatomy 0.000 claims description 7
- 239000003146 anticoagulant agent Substances 0.000 claims description 6
- 229940127219 anticoagulant drug Drugs 0.000 claims description 6
- DHMQDGOQFOQNFH-UHFFFAOYSA-M Aminoacetate Chemical compound NCC([O-])=O DHMQDGOQFOQNFH-UHFFFAOYSA-M 0.000 claims description 5
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 claims description 5
- 238000007654 immersion Methods 0.000 claims description 5
- 239000007924 injection Substances 0.000 claims description 5
- 238000002347 injection Methods 0.000 claims description 5
- 210000005036 nerve Anatomy 0.000 claims description 5
- 229910052709 silver Inorganic materials 0.000 claims description 5
- 239000004332 silver Substances 0.000 claims description 5
- 238000005516 engineering process Methods 0.000 claims description 4
- 238000007747 plating Methods 0.000 claims description 4
- 238000000338 in vitro Methods 0.000 claims description 3
- 238000011160 research Methods 0.000 abstract description 5
- 201000010099 disease Diseases 0.000 abstract description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 4
- 230000001575 pathological effect Effects 0.000 abstract description 4
- 238000002360 preparation method Methods 0.000 abstract description 3
- 229940079593 drug Drugs 0.000 abstract description 2
- 239000003814 drug Substances 0.000 abstract description 2
- 230000007246 mechanism Effects 0.000 abstract description 2
- 241001465754 Metazoa Species 0.000 description 29
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 11
- 238000012093 association test Methods 0.000 description 11
- 102000013498 tau Proteins Human genes 0.000 description 10
- 108010026424 tau Proteins Proteins 0.000 description 10
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
- 230000006399 behavior Effects 0.000 description 9
- 210000004556 brain Anatomy 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 239000012153 distilled water Substances 0.000 description 6
- 238000005406 washing Methods 0.000 description 6
- 208000019901 Anxiety disease Diseases 0.000 description 5
- 238000010171 animal model Methods 0.000 description 5
- 230000036506 anxiety Effects 0.000 description 5
- 230000001143 conditioned effect Effects 0.000 description 5
- 235000019441 ethanol Nutrition 0.000 description 5
- 230000035939 shock Effects 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 238000004043 dyeing Methods 0.000 description 4
- 230000008014 freezing Effects 0.000 description 4
- 238000007710 freezing Methods 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 238000007789 sealing Methods 0.000 description 4
- 210000003625 skull Anatomy 0.000 description 4
- 230000035943 smell Effects 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 238000012549 training Methods 0.000 description 4
- 238000011830 transgenic mouse model Methods 0.000 description 4
- 239000008096 xylene Substances 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000000971 hippocampal effect Effects 0.000 description 3
- 230000007794 irritation Effects 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 210000004940 nucleus Anatomy 0.000 description 3
- 230000007170 pathology Effects 0.000 description 3
- 239000008363 phosphate buffer Substances 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 230000001603 reducing effect Effects 0.000 description 3
- ZLPNPICUKSKARI-UHFFFAOYSA-N 2-aminoacetic acid;silver Chemical compound [Ag].NCC(O)=O ZLPNPICUKSKARI-UHFFFAOYSA-N 0.000 description 2
- 201000011240 Frontotemporal dementia Diseases 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- 108010034791 Heterochromatin Proteins 0.000 description 2
- 102000029749 Microtubule Human genes 0.000 description 2
- 108091022875 Microtubule Proteins 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 102000004243 Tubulin Human genes 0.000 description 2
- 108090000704 Tubulin Proteins 0.000 description 2
- 230000006978 adaptation Effects 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 210000003855 cell nucleus Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 208000010877 cognitive disease Diseases 0.000 description 2
- 230000013872 defecation Effects 0.000 description 2
- 230000018044 dehydration Effects 0.000 description 2
- 238000006297 dehydration reaction Methods 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 210000004458 heterochromatin Anatomy 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 210000003141 lower extremity Anatomy 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 210000004688 microtubule Anatomy 0.000 description 2
- 210000003470 mitochondria Anatomy 0.000 description 2
- 230000004770 neurodegeneration Effects 0.000 description 2
- 210000002267 nissl body Anatomy 0.000 description 2
- 210000000633 nuclear envelope Anatomy 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 210000003935 rough endoplasmic reticulum Anatomy 0.000 description 2
- -1 tau-R3 Chemical compound 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 description 1
- 238000010175 APPswe/PSEN1dE9 Methods 0.000 description 1
- 206010059245 Angiopathy Diseases 0.000 description 1
- 206010063659 Aversion Diseases 0.000 description 1
- 208000028698 Cognitive impairment Diseases 0.000 description 1
- 208000011990 Corticobasal Degeneration Diseases 0.000 description 1
- 206010013082 Discomfort Diseases 0.000 description 1
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- 102000009664 Microtubule-Associated Proteins Human genes 0.000 description 1
- 108010020004 Microtubule-Associated Proteins Proteins 0.000 description 1
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 206010034719 Personality change Diseases 0.000 description 1
- 208000000609 Pick Disease of the Brain Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 208000030886 Traumatic Brain injury Diseases 0.000 description 1
- 229910052770 Uranium Inorganic materials 0.000 description 1
- ABUBSBSOTTXVPV-UHFFFAOYSA-H [U+6].CC([O-])=O.CC([O-])=O.CC([O-])=O.CC([O-])=O.CC([O-])=O.CC([O-])=O Chemical compound [U+6].CC([O-])=O.CC([O-])=O.CC([O-])=O.CC([O-])=O.CC([O-])=O.CC([O-])=O ABUBSBSOTTXVPV-UHFFFAOYSA-H 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 238000007605 air drying Methods 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium chloride Substances Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 239000000981 basic dye Substances 0.000 description 1
- HOQPTLCRWVZIQZ-UHFFFAOYSA-H bis[[2-(5-hydroxy-4,7-dioxo-1,3,2$l^{2}-dioxaplumbepan-5-yl)acetyl]oxy]lead Chemical compound [Pb+2].[Pb+2].[Pb+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HOQPTLCRWVZIQZ-UHFFFAOYSA-H 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000009194 climbing Effects 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 210000003618 cortical neuron Anatomy 0.000 description 1
- ZXJXZNDDNMQXFV-UHFFFAOYSA-M crystal violet Chemical compound [Cl-].C1=CC(N(C)C)=CC=C1[C+](C=1C=CC(=CC=1)N(C)C)C1=CC=C(N(C)C)C=C1 ZXJXZNDDNMQXFV-UHFFFAOYSA-M 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000000249 desinfective effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000012137 double-staining Methods 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 230000021824 exploration behavior Effects 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000001879 hippocampal ca1 region Anatomy 0.000 description 1
- 210000004295 hippocampal neuron Anatomy 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 210000003140 lateral ventricle Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 206010027175 memory impairment Diseases 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 210000001700 mitochondrial membrane Anatomy 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 230000007659 motor function Effects 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000000379 polymerizing effect Effects 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 201000002212 progressive supranuclear palsy Diseases 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 1
- 229960002646 scopolamine Drugs 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 230000037152 sensory function Effects 0.000 description 1
- 230000009528 severe injury Effects 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 210000004092 somatosensory cortex Anatomy 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000012192 staining solution Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000018726 traumatic encephalopathy Diseases 0.000 description 1
- JFALSRSLKYAFGM-UHFFFAOYSA-N uranium(0) Chemical compound [U] JFALSRSLKYAFGM-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
- A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/10—Animals modified by protein administration, for non-therapeutic purpose
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0306—Animal model for genetic diseases
- A01K2267/0312—Animal model for Alzheimer's disease
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Environmental Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Zoology (AREA)
- Endocrinology (AREA)
- Pathology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Animal Husbandry (AREA)
- Gastroenterology & Hepatology (AREA)
- Biodiversity & Conservation Biology (AREA)
- Rheumatology (AREA)
- Toxicology (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Description
Claims (7)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910904177.7A CN110506708B (zh) | 2019-09-24 | 2019-09-24 | 一种阿尔茨海默症小鼠模型及评价方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910904177.7A CN110506708B (zh) | 2019-09-24 | 2019-09-24 | 一种阿尔茨海默症小鼠模型及评价方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN110506708A CN110506708A (zh) | 2019-11-29 |
CN110506708B true CN110506708B (zh) | 2021-12-17 |
Family
ID=68633533
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910904177.7A Active CN110506708B (zh) | 2019-09-24 | 2019-09-24 | 一种阿尔茨海默症小鼠模型及评价方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN110506708B (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111832531B (zh) * | 2020-07-24 | 2024-02-23 | 安徽正华生物仪器设备有限公司 | 基于深度学习适用于啮齿动物社交实验的分析系统和方法 |
CN111631190B (zh) * | 2020-08-03 | 2021-01-29 | 江苏集萃药康生物科技有限公司 | 小鼠模型在评估智力水平中的应用 |
CN113017902B (zh) * | 2021-03-05 | 2022-09-27 | 中国人民解放军军事科学院军事医学研究院 | 电磁辐射动物脑损伤模型构建方法 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108938667A (zh) * | 2018-09-28 | 2018-12-07 | 山东省科学院生物研究所 | 一种用于药物筛选的阿尔兹海默症模型的构建方法 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1604988A1 (en) * | 2004-05-18 | 2005-12-14 | Sanofi-Aventis Deutschland GmbH | Pyridazinone derivatives, methods for producing them and their use as pharmaceuticals |
-
2019
- 2019-09-24 CN CN201910904177.7A patent/CN110506708B/zh active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108938667A (zh) * | 2018-09-28 | 2018-12-07 | 山东省科学院生物研究所 | 一种用于药物筛选的阿尔兹海默症模型的构建方法 |
Non-Patent Citations (3)
Title |
---|
Al离子对tau蛋白R3多肽异常聚集的影响及其机理;王冲;《中国优秀硕士学位论文全文数据库医药卫生科技辑》;20070715(第1期);全文 * |
Zn2+ Interrupts R4-R3 Association Leading to Accelerated Aggregation of Tau Protein;Jiji,A.C;《CHEMISTRY-A EUROPEAN JOURNAL》;20171201;第23卷(第67期);全文 * |
阿尔茨海默病相关多肽与Cu2+结合性质的研;马庆丰;《中国博士学位论文全文数据库医药卫生科技辑》;20070815(第02期);全文 * |
Also Published As
Publication number | Publication date |
---|---|
CN110506708A (zh) | 2019-11-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN110506708B (zh) | 一种阿尔茨海默症小鼠模型及评价方法 | |
Wallhäusser et al. | Auditory imprinting leads to differential 2-deoxyglucose uptake and dendritic spine loss in the chick rostral forebrain | |
Oomen et al. | Early maternal deprivation affects dentate gyrus structure and emotional learning in adult female rats | |
Richards et al. | Tactile stimulation during development alters behaviour and neuroanatomical organization of normal rats | |
Le et al. | Early retinoic acid deprivation in developing zebrafish results in microphthalmia | |
Gómez et al. | Cerebellum lesion impairs eyeblink-like classical conditioning in goldfish | |
CN109512819B (zh) | 自闭症小鼠模型、其构建方法及用途 | |
Barone et al. | Behavioral assessment of vision in pigs | |
Wadhwa et al. | Quantitative study of plasticity in the auditory nuclei of chick under conditions of prenatal sound attenuation and overstimulation with species specific and music sound stimuli | |
Ikebuchi et al. | Very early development of nucleus taeniae of the amygdala | |
Cordeiro et al. | Graft-mediated functional recovery on a skilled forelimb use paradigm in a rodent model of Parkinson's disease is dependent on reward contingency | |
Jiang et al. | Early prenatal morphine exposure impairs performance of learning tasks and attenuates in vitro heterosynaptic long-term potentiation of intermediate medial mesopallium in day-old chicks | |
CN110013546B (zh) | 一种cpsp动物模型的建立方法及应用 | |
McCall et al. | Development of neuronal responses in cat posteromedial lateral suprasylvian visual cortex | |
CN116210637A (zh) | 一种成瘾药物戒断后复吸相关调控基因及其筛选方法 | |
Yao et al. | Prolonged early exposure to a high-fat diet augments the adverse effects on Neurobehavior and hippocampal neuroplasticity: involvement of microglial insulin signaling | |
CN112931398A (zh) | 一种狼疮脑病动物模型的构建方法及其应用 | |
Pan et al. | Agonistic behaviors and neuronal activation in sexually naïve female Mongolian gerbils | |
Liao et al. | HDAC2 inhibe la neurogenesis del hipocampo y afecta la funcion cognitiva en la descendencia adulta estresada prenatalmente | |
Liao et al. | HDAC2 Inhibits Hippocampal Neurogenesis and Impairs the Cognitive Function in Prenatally Stressed Adult Offspring. | |
CN109152350A (zh) | 呈现出由蛋白质凝聚引起的退行性症状的非人动物 | |
Kesar | Effect of prenatal chronic excessive sound exposure on auditory filial imprinting area of chick forebrain | |
Francis-Malave et al. | Sex differences in pain-related behaviors and clinical progression of disease in mouse models of visceral pain | |
Stenstrom et al. | The Direction of response selectivity between conspecific and heterospecific auditory stimuli varies with response metric | |
VIJAYA | Development of a model of Parkinson’s disease in Acomys cahirinus |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
EE01 | Entry into force of recordation of patent licensing contract | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20191129 Assignee: Shenzhen Dongfang Renshou Life Technology Co.,Ltd. Assignor: SHENZHEN University Contract record no.: X2022980025926 Denomination of invention: A mouse model of Alzheimer's disease and its evaluation method Granted publication date: 20211217 License type: Common License Record date: 20221211 |
|
EE01 | Entry into force of recordation of patent licensing contract | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20191129 Assignee: Shenzhen Haichuang Marine Technology Co.,Ltd. Assignor: SHENZHEN University Contract record no.: X2022980026596 Denomination of invention: A mouse model of Alzheimer's disease and its evaluation method Granted publication date: 20211217 License type: Common License Record date: 20221212 Application publication date: 20191129 Assignee: Shenzhen Qike E-commerce Co.,Ltd. Assignor: SHENZHEN University Contract record no.: X2022980026362 Denomination of invention: A mouse model of Alzheimer's disease and its evaluation method Granted publication date: 20211217 License type: Common License Record date: 20221212 |
|
EE01 | Entry into force of recordation of patent licensing contract | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20191129 Assignee: SHENZHEN TAIFENG DONGFANG OCEAN BIOTECHNOLOGY Co.,Ltd. Assignor: SHENZHEN University Contract record no.: X2023980033970 Denomination of invention: A mouse model of Alzheimer's disease and its evaluation method Granted publication date: 20211217 License type: Common License Record date: 20230322 |
|
EE01 | Entry into force of recordation of patent licensing contract | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20191129 Assignee: SHENZHEN SUPERVISIONS TECHNOLOGY Co.,Ltd. Assignor: SHENZHEN University Contract record no.: X2023980035111 Denomination of invention: A mouse model and evaluation method for Alzheimer's disease Granted publication date: 20211217 License type: Common License Record date: 20230426 |
|
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20191129 Assignee: Shenzhen Ruikanghua Medical Technology Co.,Ltd. Assignor: SHENZHEN University Contract record no.: X2023980045608 Denomination of invention: A mouse model and evaluation method for Alzheimer's disease Granted publication date: 20211217 License type: Common License Record date: 20231103 Application publication date: 20191129 Assignee: Shenzhen kangruihua Medical Technology Co.,Ltd. Assignor: SHENZHEN University Contract record no.: X2023980045648 Denomination of invention: A mouse model and evaluation method for Alzheimer's disease Granted publication date: 20211217 License type: Common License Record date: 20231103 |
|
EE01 | Entry into force of recordation of patent licensing contract | ||
EE01 | Entry into force of recordation of patent licensing contract | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20191129 Assignee: Shenzhen Yunchuang Netcom Information Technology Co.,Ltd. Assignor: SHENZHEN University Contract record no.: X2023980047247 Denomination of invention: A mouse model and evaluation method for Alzheimer's disease Granted publication date: 20211217 License type: Common License Record date: 20231116 Application publication date: 20191129 Assignee: Guangdong Haipeng Cloud Intelligent Technology Co.,Ltd. Assignor: SHENZHEN University Contract record no.: X2023980047226 Denomination of invention: A mouse model and evaluation method for Alzheimer's disease Granted publication date: 20211217 License type: Common License Record date: 20231115 Application publication date: 20191129 Assignee: Shenzhen Changyu Health Technology Co.,Ltd. Assignor: SHENZHEN University Contract record no.: X2023980047223 Denomination of invention: A mouse model and evaluation method for Alzheimer's disease Granted publication date: 20211217 License type: Common License Record date: 20231115 Application publication date: 20191129 Assignee: Changyu Health Technology (Dongguan) Co.,Ltd. Assignor: SHENZHEN University Contract record no.: X2023980047216 Denomination of invention: A mouse model and evaluation method for Alzheimer's disease Granted publication date: 20211217 License type: Common License Record date: 20231115 Application publication date: 20191129 Assignee: Shenzhen Suowei Information Technology Co.,Ltd. Assignor: SHENZHEN University Contract record no.: X2023980047180 Denomination of invention: A mouse model and evaluation method for Alzheimer's disease Granted publication date: 20211217 License type: Common License Record date: 20231115 |
|
EE01 | Entry into force of recordation of patent licensing contract | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20191129 Assignee: Guangdong Whale Biotechnology Co.,Ltd. Assignor: SHENZHEN University Contract record no.: X2023980048812 Denomination of invention: A mouse model and evaluation method for Alzheimer's disease Granted publication date: 20211217 License type: Common License Record date: 20231129 Application publication date: 20191129 Assignee: Guangdong Bonn Life Sciences Co.,Ltd. Assignor: SHENZHEN University Contract record no.: X2023980048412 Denomination of invention: A mouse model and evaluation method for Alzheimer's disease Granted publication date: 20211217 License type: Common License Record date: 20231127 |
|
EE01 | Entry into force of recordation of patent licensing contract | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20191129 Assignee: Shenzhen Citizen Jishidai Technology Co.,Ltd. Assignor: SHENZHEN University Contract record no.: X2023980052689 Denomination of invention: A mouse model and evaluation method for Alzheimer's disease Granted publication date: 20211217 License type: Common License Record date: 20231218 |
|
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20191129 Assignee: Shenzhen Hepulos Medical System Technology Co.,Ltd. Assignor: SHENZHEN University Contract record no.: X2024980000266 Denomination of invention: A mouse model and evaluation method for Alzheimer's disease Granted publication date: 20211217 License type: Common License Record date: 20240108 |
|
EE01 | Entry into force of recordation of patent licensing contract |